-
Something wrong with this record ?
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment
K. Chroma, Z. Skrott, J. Gursky, J. Bacovsky, P. Moudry, T. Buchtova, M. Mistrik, J. Bartek
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
Freely Accessible Science Journals
from 2010
Nature Open Access
from 2010-01-01
PubMed Central
from 2010
Europe PubMed Central
from 2010
ProQuest Central
from 2010-01-01
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
Health & Medicine (ProQuest)
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
Springer Nature OA/Free Journals
from 2010-01-01
- MeSH
- Bortezomib pharmacology therapeutic use MeSH
- Drug Resistance, Neoplasm MeSH
- Disulfiram pharmacology MeSH
- Proteasome Inhibitors pharmacology therapeutic use MeSH
- Humans MeSH
- Neoplasm Recurrence, Local drug therapy MeSH
- Multiple Myeloma * pathology MeSH
- Cell Line, Tumor MeSH
- Drug Repositioning MeSH
- Proteasome Endopeptidase Complex metabolism MeSH
- Antineoplastic Agents * pharmacology therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome with specific inhibitors (PI). The resulting interference with protein degradation is particularly toxic to MM cells as they typically accumulate large amounts of toxic proteins. However, MM cells often acquire resistance to PIs through aberrant expression or mutations of proteasome subunits such as PSMB5, resulting in disease recurrence and further treatment failure. Here we propose CuET-a proteasome-like inhibitor agent that is spontaneously formed in-vivo and in-vitro from the approved alcohol-abuse drug disulfiram (DSF), as a readily available treatment effective against diverse resistant forms of MM. We show that CuET efficiently kills also resistant MM cells adapted to proliferate under exposure to common anti-myeloma drugs such as bortezomib and carfilzomib used as the first-line therapy, as well as to other experimental drugs targeting protein degradation upstream of the proteasome. Furthermore, CuET can overcome also the adaptation mechanism based on reduced proteasome load, another clinically relevant form of treatment resistance. Data obtained from experimental treatment-resistant cellular models of human MM are further corroborated using rather unique advanced cytotoxicity experiments on myeloma and normal blood cells obtained from fresh patient biopsies including newly diagnosed as well as relapsed and treatment-resistant MM. Overall our findings suggest that disulfiram repurposing particularly if combined with copper supplementation may offer a promising and readily available treatment option for patients suffering from relapsed and/or therapy-resistant multiple myeloma.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019223
- 003
- CZ-PrNML
- 005
- 20220804135439.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41419-022-04651-w $2 doi
- 035 __
- $a (PubMed)35246527
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Chroma, Katarina $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000301410469
- 245 12
- $a A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment / $c K. Chroma, Z. Skrott, J. Gursky, J. Bacovsky, P. Moudry, T. Buchtova, M. Mistrik, J. Bartek
- 520 9_
- $a Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome with specific inhibitors (PI). The resulting interference with protein degradation is particularly toxic to MM cells as they typically accumulate large amounts of toxic proteins. However, MM cells often acquire resistance to PIs through aberrant expression or mutations of proteasome subunits such as PSMB5, resulting in disease recurrence and further treatment failure. Here we propose CuET-a proteasome-like inhibitor agent that is spontaneously formed in-vivo and in-vitro from the approved alcohol-abuse drug disulfiram (DSF), as a readily available treatment effective against diverse resistant forms of MM. We show that CuET efficiently kills also resistant MM cells adapted to proliferate under exposure to common anti-myeloma drugs such as bortezomib and carfilzomib used as the first-line therapy, as well as to other experimental drugs targeting protein degradation upstream of the proteasome. Furthermore, CuET can overcome also the adaptation mechanism based on reduced proteasome load, another clinically relevant form of treatment resistance. Data obtained from experimental treatment-resistant cellular models of human MM are further corroborated using rather unique advanced cytotoxicity experiments on myeloma and normal blood cells obtained from fresh patient biopsies including newly diagnosed as well as relapsed and treatment-resistant MM. Overall our findings suggest that disulfiram repurposing particularly if combined with copper supplementation may offer a promising and readily available treatment option for patients suffering from relapsed and/or therapy-resistant multiple myeloma.
- 650 12
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a bortezomib $x farmakologie $x terapeutické užití $7 D000069286
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a disulfiram $x farmakologie $7 D004221
- 650 _2
- $a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mnohočetný myelom $x patologie $7 D009101
- 650 _2
- $a lokální recidiva nádoru $x farmakoterapie $7 D009364
- 650 _2
- $a proteasomový endopeptidasový komplex $x metabolismus $7 D046988
- 650 _2
- $a inhibitory proteasomu $x farmakologie $x terapeutické užití $7 D061988
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Skrott, Zdenek $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000160043609
- 700 1_
- $a Gursky, Jan $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Bacovsky, Jaroslav $u Department of Hemato-oncology, University Hospital Olomouc and Medical Faculty of Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Moudry, Pavel $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/000000021479007X
- 700 1_
- $a Buchtova, Tereza $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000152331504
- 700 1_
- $a Mistrik, Martin $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. martin.mistrik@upol.cz $1 https://orcid.org/0000000223210348
- 700 1_
- $a Bartek, Jiri $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. jb@cancer.dk $u Danish Cancer Society Research Center, Copenhagen, Denmark. jb@cancer.dk $u Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden. jb@cancer.dk $1 https://orcid.org/0000000320137525 $7 xx0046271
- 773 0_
- $w MED00173233 $t Cell death & disease $x 2041-4889 $g Roč. 13, č. 3 (2022), s. 203
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35246527 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135433 $b ABA008
- 999 __
- $a ok $b bmc $g 1822706 $s 1170466
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 13 $c 3 $d 203 $e 20220304 $i 2041-4889 $m Cell death & disease $n Cell Death Dis $x MED00173233
- LZP __
- $a Pubmed-20220720